Autopsy report · NCT04944654
Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH
Cause of deathFunding or business, also drug or device supply
“Trial set up was delayed, funding support no longer available”
Life of this trial
- Registered 1 year 7 months before it started.
- Ran for about 4 months before it stopped.
- 1 participant enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Conditions
- Human Immunodeficiency Virus
- Interventions
- BIKTARVY 50Mg-200Mg-25Mg Tablet
- Participants
- 1
- Sites
- 1
- Countries
- United Kingdom
Trials that died the same way
- A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
“Trial was cancelled by Sponsor” - Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
“The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.” - Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris
“Lack of funding and sponsor decided to not pursue clinical trial” - A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
“Trial was stopped due to difficult enrolment” - A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk
“Funding no longer available”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.